Close, continuous, and real-time monitoring of atrial fibrillation using the CardiacSense Watch

Atrial fibrillation (A-Fib) is associated with an increased risk of stroke and heart failure, due to the high potential of clot formation caused by an abnormal heart rate. Therefore, patients with diagnosed A-Fib require close monitoring to detect and manage the serious consequences of the condition.

  • 14-30% of strokes are caused by A-Fib depending on various factors1,2.
  • Patients with untreated A-Fib have three to five times greater risk of stroke and have worse progression3.
  • Since 1/3 of people over the age of 55 experience A-Fib4, close and continuous monitoring of patients at home or electrophysiology lab could save many lives.

The CardiacSense watch is a certified medical device for continuous (24/7), non-invasive, real-time monitoring and detection of patients with A-Fib. The device contains a photoplethysmograph (PPG) and a one-lead electrocardiogram (ECG), giving it the ability to measure heart rate and heart rate variability, catching the critical signs that intermittent measurements can miss.

In a comparison study, all A-Fib events detected by physicians based on Holter ECG were also detected by the CardiacSense watch5. With a sensitivity and specificity rate of above 95%5, the CardiacSense watch provides accurate data for healthcare providers, facilitating their diagnoses and treatment decisions. This is made even easier through the Physician portal that allows practitioners to consult data at their own convenience and set up personalized alerts.

[1] Heart and Stroke Foundation of Canada,

[2] CDC, 2022,

[3] Yang, S. Y., Huang, M., Wang, A. L., Ge, G., Ma, M., Zhi, H., & Wang, L. N. (2022). Atrial fibrillation burden and the risk of stroke: A systematic review and dose-response meta-analysis. World journal of clinical cases, 10(3), 939–953.

[4] Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018 Apr 26;361:k1453. doi: 10.1136/bmj.k1453. PMID: 29699974; PMCID: PMC5917175.

[5] CardiacSense, A Prospective, Open, Multi-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation, 2020

Wearing the CardiacSense watch can help detect asymptomatic A-fib and prevent deterioration in patients.

Request more information about the CardiacSense watch: